https://www.delveinsight.com/asco-conference/article/abbvies-telisotuzumab-vedotin?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage

1. AbbVie’s Telisotuzumab
Vedotin (Teliso-V)
Demonstrated Encouraging
Responses In C-MET NSCLC
Patients Who Progressed on
Previous Treatments

2. Phase II study of telisotuzumab vedotin in patients with c–MET+ NSCLC who have
previously received not more than 2 lines prior systemic therapy (Abstract # 9016)
An anti-c-MET antibody-drug conjugate (ADC) called telisotuzumab vedotin is
made up of a monoclonal antibody attached to monomethyl auristatin E.
(MMAE). In the Phase I Study (MN14-237), Teliso-V and osimertinib are given to
patients with previously treated NSCLC who have c-MET overexpression. Recently,
the FDA granted the medication Breakthrough Therapy Designation (BTD) for use
as monotherapy in patients with metastatic or advanced EGFR-wt non-squamous
NSCLC whose cancer has progressed or grown after receiving platinum-based
therapy.
Results of patients treated with Teliso-V and osimertinib in Phase I/Ib who had
EGFR L858R, ex 19 deletions, and overexpression of c-MET. An ORR of 58 percent
was seen when Teliso-V and osimertinib were combined. According to its
recommended dosage, Teliso-V had an ORR of 3 (43%) out of 7 patients receiving
1.6 mg/kg and 8 (67%) out of 12 patients receiving 1.9 mg/kg.
A preliminary analysis from the Phase II LUMINOSITY trial, which involved 136
patients and of whom 122 could be evaluated for the main outcome, was given by
AbbVie. The objective response rate (ORR) as determined by an impartial central
review served as the primary endpoint. The Bayesian model predicts that stage 2
advancement is more likely if at least 70% of the genuine ORR is present. 131
(96%) of patients experienced treatment-emergent adverse events (TEAEs) of any
grade, and 65 patients experienced Grade 3+ adverse events (48 percent of
patients).
KOL insights
“Patients with NSCLC have a high unmet need, and telisotuzumab vedotin has the
potential to provide them with an additional treatment option to manage their
disease.”–Expert Opinion.
Conclusion
The effectiveness of both cytotoxic chemotherapy and targeted therapy is
affected by the anti-cancer treatment class known as antibody-drug conjugates
(ADCs), which can deliver cytotoxic medications directly to tumour cells. The use
of ADCs is expanding quickly, and early research in lung cancer has produced

3. encouraging results. ADCs that target HER2, HER3, TROP2, CEACAM5, and MET
are now being tested in clinical studies for NSCLC.
Oncogene tyrosine kinase receptor (c-MET) is the term used to describe this
substance. Numerous cellular processes can be regulated by c-MET, and when
these processes are dysregulated, tumour cells are more likely to proliferate,
survive, invade, and spread. Point mutations, amplification, fusion, and protein
overexpression are c-MET changes found in NSCLC that are linked to a poor
prognosis.
MET activation has previously been implicated as both a primary oncogenic driver
mutation and a secondary driver of acquired resistance to targeted therapy in
other genomic subpopulations, according to preclinical and clinical investigations.
Agents that target c-MET are thus a possible therapeutic approach for NSCLC.
There isn't currently a targeted medication that specifically targets NSCLC with c-
MET overexpression. Therefore, obtaining a BTD can be essential in securing
approval for the primary therapy in this patient group by providing this chemical.
Companies- Janssen, Cullinan Oncology, Immutep, Bristol Myers Squibb, Merck
Sharp & Dohme, Surface Oncology, AbbVie, Daiichi Sankyo, Chugai
Pharmaceutical, Regeneron, Sanofi, and others.
Get in touch with our Business Expert @ Business Consulting Services | Biotech
Consulting | Technical Due Diligence Firms
About ASCO 2022 Conference Updates
asco 2021 highlights | asco highlights 2021 | asco medical conference | asco
2021 | asco 2021 conference | when is asco 2021 | 2021 asco | 2021 asco annual
meeting | asco convention | asco conference 2021 | asco 2021 | asco 21 | asco
us | asco 2022 annual meeting | asco abstract 2022